Stock OBI ONDINE BIOMEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Delayed London S.E.
Other stock markets
 10:23:41 2024-06-11 am EDT 		5-day change 1st Jan Change
7.72 GBX +6.48% Intraday chart for Ondine Biomedical Inc. -6.42% -11.77%
Jun. 10 Transcript : Ondine Biomedical Inc., 2023 Earnings Call, Jun 10, 2024
Jun. 07 Ondine Biomedical loss narrows as revenue soars 88% in 2023 AN

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ONDINE BIOMEDICAL INC. Stock Ondine Biomedical Inc.
-11.77% 25.58M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.64% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-0.15% 109B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-2.46% 69.22B
A
DEXCOM, INC. Stock DexCom, Inc.
-6.05% 46.36B
B-
CENCORA, INC. Stock Cencora, Inc.
+13.48% 46.19B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.48% 42.44B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+17.99% 30.84B
B
TERUMO CORPORATION Stock Terumo Corporation
+19.69% 25.73B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.91% 23.3B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
  1. Stock Market
  2. Equities
  3. OBI Stock
  4. Ratings Ondine Biomedical Inc.